26 results
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
clinical care outcomes. We plan to present the Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024. We also initiated a
S-3
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
Nerve Society Annual Meeting on June 25, 2024. We also initiated a
S-3
real-world evidence, or RWE, protocol with International Guillain-Barré Syndrome
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
to present Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024.
ANX005 has been granted Fast Track and Orphan Drug
8-K
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Society Annual Meeting on June 25, 2024.
GBS is a rapid and acute neurological disease with a narrow therapeutic window that results
8-K
EX-99.1
159cde3i53kmioeb
4 Mar 24
Regulation FD Disclosure
5:25pm
424B5
snan0zb j1w0oevt68
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
4owrmvh
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.3
rwjn9pb2zr3cs0g
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
nat0pdgg3bw0ek
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
xag6xq5
24 Oct 23
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
4:30pm
8-K
EX-99.1
sa7c82o11f j1jh5or
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.2
kdrahh7z3ri1c kr1
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
z0m2vddu 0saxft
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
rd201nt1j5zo9cd57b60
16 Aug 21
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
4:11pm
424B4
aqt5q09eqyef036ysui
24 Jul 20
Prospectus supplement with pricing info
5:15pm